Chugai Pharmaceutical Co., Ltd. risk profile
35 Normal where most of the sector sits
Measured 1 September 2026 from 4519's filed statements. Recomputed nightly.
35 (Normal), driven by Market expectation at 50, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 50 | Elevated | Stable | One-year price volatility — 40.2% |
| Operating pressure | 30 | Normal | Worsening | Costs outgrowing revenue — -2.6 percentage points |
| Cash conversion | 20 | Normal | Worsening | Capital spending against operating cash — 0.29x |
| Leverage and coverage | Reads total_debt, cash_and_cash_equivalents, ebitda, interest_expense, total_current_assets, total_current_liabilities and a disclosed CET1 ratio, for a bank or insurer. No reading is stored for this company. | |||
| Competitive position | 38 | Normal | Stable | Revenue-growth gap against peers — -30.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Chugai Pharmaceutical Co., Ltd.